Test score may predict which prostate cancer patients can safely skip combined therapy

Questions To Ask Your Health Care Provider

• What test will predict the risk of my cancer spreading?
• What are my options for treating prostate cancer?
• What side effects may be associated with my treatment?
• Is taking a combined- (or multi-) therapy approach necessary for my prostate cancer?

Open Clinical Trials

The following studies are enrolling people with early-stage prostate cancer.  

• NCT05498272: NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer. This study is enrolling people with intermediate-risk or high-risk prostate cancer with the cerain gene mutations who are planning to undergo surgery to have their prostate removed (radical prostatectomy). 
• NCT04404894: Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing. This registry evaluates treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing—a risk estimating test. It measures the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment as well as clinical outcomes.
• NCT03697148: MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer. This study evaluates how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning for patients with prostate cancer. 
• NCT04396808: Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer. This study looks at a new ways to use tumor testing and other tools to help patients understand their risk for recurrence and make decisions about their care after early-stage prostate cancer. 

Several other clinical trials for patients with early-stage prostate can be found here.